Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule
SEATTLE, Sept. 19, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced that it has received a letter from The NASDAQ Stock Market LLC (the "NASDAQ"), indicating that CTI has regained compliance with the minimum bid price rule (NASDAQ Listing Rule 5550(a)(2)) .
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.
Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room
Investors Contact:
Ed Bell
T: 206.282.7100
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors
SOURCE Cell Therapeutics, Inc.
RELATED LINKS
http://www.celltherapeutics.com
More by this Source
Gemeinsamer Bundesausschuss (G-BA) gibt Beschluss über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V für Pixantron (Pixuvri®) bekannt.
May 21, 2013, 01:30 ET
German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRI® (pixantrone)
May 20, 2013, 01:30 ET
Cell Therapeutics to Present at Upcoming Investor Conferences
May 15, 2013, 01:30 ET
Featured Video
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.